Frequently Asked Questions
Factors such as recent advances in the vaccine development for MERS and rising demand for oral drugs are acting as the major drivers for the global Middle East respiratory syndrome (MERS) market.
The major players are GeneOne Life Science (South Korea), INOVIO Pharmaceuticals (U.S.), Pfizer Inc.(U.S.), Regeneron Pharmaceuticals Inc (U.S.), Astellas Pharma Inc. (Japan), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries Ltd (Israel)
The major countries covered in the Middle East Respiratory Syndrome (MERS) Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The segments analyzed in the report are product, route of administration, distribution channel and end-user.
